Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | WGI-0301 |
Synonyms | |
Therapy Description |
WGI-0301 is a lipid nanoparticle-based formulation of archexin, an antisense oligonucleotide targeting Akt, which inhibits Akt1 translation and potentially leads to decreased proliferation of Akt1-overexpressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WGI-0301 | WGI 0301|WGI0301 | Antisense Therapy 13 | WGI-0301 is a lipid nanoparticle-based formulation of archexin, an antisense oligonucleotide targeting Akt, which inhibits Akt1 translation and potentially leads to decreased proliferation of Akt1-overexpressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05267899 | Phase I | WGI-0301 | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |